

Bayer HealthCare
Pharmaceuticals

RECEIVED
CENTRAL FAX CENTER
JUN 16 2006



To **Commissioner for Patents**
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Fax (571) 273-8300 Pages 3 (including cover sheet)

Date June 16, 2006

From Susan M. Pellegrino

Fax (203) 812-6459 Tel. (203) 812-6450

Re U.S. Patent Application Serial No.: 10/719,485

Bayer Pharmaceuticals
Corporation

400 Morgan Lane
West Haven, CT 06516

Phone: (203) 812-6450

Fax: (203) 812-6459

E-mail:

susan.pellegrino.b@bayer.com

For U.S. Patent Application Serial No. 10/719,485

- 1) Response to Office Action mailed on May 17, 2006
- 2) Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

If you have any problems with the attached facsimile call (203) 812-6450.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT THE PRIVILEGED OR CONFIDENTIAL NATURE OF THIS MESSAGE IS NOT WAIVED BY INADVERTENT DISCLOSURE. ANY DISSEMINATION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

RECEIVED
CENTRAL FAX CENTER

JUN 16 2006

PTO/SB/97 (05-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on June 16, 2006
Date

Susan M. Pellegrino
Signature

Susan M. Pellegrino, Reg. No. 48,972

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

For U.S. Patent Application Serial No. 10/719,485

- 1) Reply to Office Action mailed on May 17, 2006
- 2) Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. 5146

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
JUN 16 2006

In re Patent Application of Joachim Rudolph, et al.

Serial No.: 10/719,485

Group Art Unit: 1626

Filed: November 21, 2003

Examiner: Kamal A. Saeed

For: Anilinopyrazole Derivatives Useful for the Treatment of Diabetes

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(u)

I hereby certify that this correspondence and any papers referred to as attached are being facsimile transmitted to the U.S. Patent and Trademark Office at (571) 273-8300.

Date: June 16, 2006


Susan M. Pellegrino

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

This is in response to the Office Action mailed May 17, 2006. In response to the restriction requirement, Applicants elect the claims of restriction Group I, claims 1-17, 41, 42, and 44, directed to compounds of Formula (I), for further prosecution in this application. In addition, Applicants elect Example 175 (5-methoxy-2-{{4-(6-methoxypyridin-3-yl)-3-methyl-1-(2-methylphenyl)-1H-pyrazol-5-yl}amino}benzoic acid) found on page 68 of the specification (Table 3a) as the species for further prosecution in this application.

If there are any fees due in connection with the filing of the present response, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Date: June 16, 2006


Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450